New HIV medication gets WHO approval
An antiretroviral drug dolutegravir, popularly known as DTG, is now certified safe for use by pregnant women and incubating moms by the World Health Organisation (WHO).
Although previous research had linked the drug with neural tube defects (NTDs) in infants born to women using dolutegravir. At the time of conception, latest studies shows it was far more better than the older drug efavirenz. Which patients have noted causes depression and hallucinations in the initial months and might cause abandonment of treatment.
“DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to efavirenz and nevirapine-based regimens,” states the WHO.
WHO in a statement released on its official website on Monday, said that the DTG drug was now more effective. To take with fewer side effects than alternative drugs.
“DTG also has a high genetic barrier to developing drug resistance, which is important. Given the rising trend of resistance to EFV and nevirapine-based regimens.
“In 2019, 12 out of 18 countries surveyed by WHO reported pre-treatment drug resistance levels. Exceeding the recommended threshold of 10 per cent.
“All of above findings informed the decision to update the 2019 guidelines, and the newly updated recommendations. Aim to help more countries improve their HIV policies,” WHO said.
”For any medications, informed choice is important as every treatment decision needs to be based on an informed discussion. With the health provider weighing the benefits and potential risks,” it said